医药行业的人才迁徙,本质上反应的是中国医药产业在转型升级中,人力资源与企业发展阶段相匹配后的结果。医药行业人才流向的拐点,也是行业发展的拐点。撰文| 张烨静金九银十,医药行业迎来一波密集的高层人事变动,多家本土药企不约而同地迎来具有跨国背景的新高管。仅近几日就有多起关键任命落地:10月9日,礼来中国抗肿瘤事业部前副总裁尹航履新恒瑞医药,出任肿瘤事业部总经理;同一天,复星医药前董事长吴以芳宣布加盟...
Source Link医药行业的人才迁徙,本质上反应的是中国医药产业在转型升级中,人力资源与企业发展阶段相匹配后的结果。医药行业人才流向的拐点,也是行业发展的拐点。撰文| 张烨静金九银十,医药行业迎来一波密集的高层人事变动,多家本土药企不约而同地迎来具有跨国背景的新高管。仅近几日就有多起关键任命落地:10月9日,礼来中国抗肿瘤事业部前副总裁尹航履新恒瑞医药,出任肿瘤事业部总经理;同一天,复星医药前董事长吴以芳宣布加盟...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.